Vital Signs - Healthcare News - The Analyst's Perspective February 2014 Issue
This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm' and what these deals mean for the industry. Additionally, Illumina's first stab at personalized medicine through a partnership with Amgen is explored.
The Californian sequencing instrumentation leader, Illumina, entered into a partnership with Amgen to develop and commercialize a multigene next generation sequencing (NGS) based companion diagnostic test for the targeted drug Vectibix in metastatic colorectal cancer. This partnership marks Illumina’s entry into the NGS personalized medicine segment.
The Analyst’s Perspective by Divyaa Ravishankar, Senior Industry Analyst, Life Science North America
Various life science tools manufacturers have entered the companion diagnostic market segment in the last two years. The Amgen-Illumina partnership will be developing one of the first NGS-based companion diagnostic assays. The partnership leverages Illumina’s market leadership in NGS research platforms. The partnership also delivers a geographic advantage in the U.S. and Europe, which leads to an easier roadmap to address regulatory challenges. Illumina’s MiSeq sequencer has lowered the cost of sequencing relative to the competition, making it a suitable platform to develop the multi-gene test. Amgen partnered with Illumina for its strong track record in the commercialization of novel personalized medicine products. Examples include a partnership with DxS in 2008 for the KRAS companion diagnostic test and a partnership with Dako in 2012 for another companion diagnostic test associated with a rare cancer treatment.
NGS enables patient tumor genetic profiling and the NGS market segment is rapidly moving toward clinical diagnostics for its advantages to detect a large number of mutations simultaneously and affordably. Resulting from this work, physicians can choose the best possible treatment option personalized to the patient. In the next few years, Illumina will reap benefits from this novel diagnostic test, which will position the company in the high growth companion diagnostic segment.
Electronic Access - Single User Fulfilled By Publisher
Electronic Access - Global Site License Fulfilled By Publisher